Compugen Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Sales 2024 * | 37.04M 13.34B | Sales 2025 * | 41.12M 14.81B | Capitalization | 158M 56.75B |
---|---|---|---|---|---|
Net income 2024 * | -4M -1.44B | Net income 2025 * | -1M -360M | EV / Sales 2024 * | 4.25 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.83 x |
P/E ratio 2024 * |
-35.2
x | P/E ratio 2025 * |
352
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-12-31 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 22-10-31 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 17-10-01 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 18-06-10 |
Gilead Halevy
BRD | Director/Board Member | 57 | 18-06-10 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |